Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (BEIGF) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for BeOne Medicines (BEIGF) over the last 11 years, with Q3 2025 value amounting to $1.0 billion.

  • BeOne Medicines' Accumulated Expenses rose 3963.49% to $1.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 billion, marking a year-over-year increase of 3963.49%. This contributed to the annual value of $803.7 million for FY2024, which is 1585.37% up from last year.
  • Per BeOne Medicines' latest filing, its Accumulated Expenses stood at $1.0 billion for Q3 2025, which was up 3963.49% from $908.9 million recorded in Q2 2025.
  • BeOne Medicines' 5-year Accumulated Expenses high stood at $1.0 billion for Q3 2025, and its period low was $312.1 million during Q1 2021.
  • Moreover, its 5-year median value for Accumulated Expenses was $558.1 million (2021), whereas its average is $575.8 million.
  • Per our database at Business Quant, BeOne Medicines' Accumulated Expenses surged by 9183.06% in 2021 and then rose by 16.89% in 2023.
  • Over the past 5 years, BeOne Medicines' Accumulated Expenses (Quarter) stood at $558.1 million in 2021, then increased by 11.01% to $619.5 million in 2022, then grew by 11.99% to $693.7 million in 2023, then increased by 15.85% to $803.7 million in 2024, then grew by 24.63% to $1.0 billion in 2025.
  • Its Accumulated Expenses was $1.0 billion in Q3 2025, compared to $908.9 million in Q2 2025 and $692.2 million in Q1 2025.